18 research outputs found
Recommended from our members
Reconstructing Native American Migrations from Whole-Genome and Whole-Exome Data
Recommended from our members
Reconstructing Native American Migrations from Whole-Genome and Whole-Exome Data
Sequencing rare and common APOL1 coding variants to determine kidney disease risk
A third of African Americans with sporadic focal segmental glomerulosclerosis (FSGS) or HIV-associated nephropathy (HIVAN) do not carry APOL1 renal risk genotypes. This raises the possibility that other APOL1 variants may contribute to kidney disease. To address this question, we sequenced all APOL1 exons in 1437 Americans of African and European descent, including 464 patients with biopsy-proven FSGS/HIVAN. Testing for association with 33 common and rare variants with FSGS/HIVAN revealed no association independent of strong recessive G1 and G2 effects. Seeking additional variants that might have been under selection by pathogens and could represent candidates for kidney disease risk, we also sequenced an additional 1112 individuals representing 53 global populations. Except for G1 and G2, none of the 7 common codon-altering variants showed evidence of selection or could restore lysis against trypanosomes causing human African trypanosomiasis. Thus, only APOL1 G1 and G2 confer renal risk, and other common and rare APOL1 missense variants, including the archaic G3 haplotype, do not contribute to sporadic FSGS and HIVAN in the US population. Hence, in most potential clinical or screening applications, our study suggests that sequencing APOL1 exons is unlikely to bring additional information compared to genotyping only APOL1 G1 and G2 risk alleles.SCOPUS: cp.jinfo:eu-repo/semantics/publishe
Figure S4 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors
Figure S4 contains cytotoxicity assay and immunoblot data from the MCF7 and MCF7 DpVp300 cell lines showing that expression of METTL7A confers resistance.</p
Figure S1 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors
Figure S1 contains chemical structures of select HDAC inhibitors</p
Supplemental Table S8 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors
Supplemental Table S8 contains information about METTL7A and METTL7B in T-cell lymphoma tissue microarray samples</p
Supplemental Table S5 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors
Supplemental Table S5 contains information about the cross-resistance profile of the MCF7, MCF7 DpVp300, and METTL7A knockout clones</p
Supplemental Table S3 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors
Supplemental Table S3 contains information from high-throughput sequencing</p
Figure S2 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors
Figure S2 contains cell cycle analysis and cytotoxicity data for MCF7 DpVp300 cells showing they are resistant to romidepsin and do not overexpress P-gp</p